Connect with us


Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch

Biotech penny stocks to watch this week.
The post Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch appeared first on Penny Stocks…



If you’re an active trader or looking for stock market news today, this is probably the one-millionth headline you’ve read with the phrase “Recession Begins” in the title. Apologies for that, but it’s true; we’re officially in a technical recession. For those unfamiliar with the definition of a recession, it’s two consecutive quarters of negative GDP growth.

Today’s second quarter GDP data showed that Q2’s gross domestic product fell 0.9%. This came after the first quarter’s contraction of 1.6% and a staunch difference from how the year ended in 2021. With the definition of recession being met, some may find it interesting that markets aren’t completely failing. That’s likely because of a tighter labor market and that consumers are still spending. Nevertheless, the point is that (for now) recession isn’t scaring the stock market today.

Better yet, there is still somewhat of a risk-on appetite for things like penny stocks. Today we look at the biotech sector for some of the hot stocks to watch today. While the overall biotech market is trending lower, small- and micro-cap stocks are giving some reprieve at the moment.

Biotech Penny Stocks To Watch

  1. Comera Life Sciences Holdings (NASDAQ: CMRA)
  2. Athersys, Inc. (NASDAQ: ATHX)
  3. InflaRx N.V. (NASDAQ: IFRX)
  4. Revelation Biosciences Inc. (NASDAQ: REVB)
  5. Chimerix (NASDAQ: CMRX)

Comera Life Sciences Holdings (NASDAQ: CMRA)

Comera Life Sciences is one of the penny stocks to watch as shares have steadily risen this week. The company specializes in transitioning IV medicines to subcutaneous forms and provides patients with self-injectable care.

Earlier this month, Comera announced preclinical topline safety results of its SQore excipient platform.

“The results of this preclinical study provide supportive evidence of the safety of Comera’s lead caffeine-based SQore excipient when administered as a subcutaneous (SQ) biologic drug product formulation with a monoclonal antibody (mAb).”

While the headline came out on the 13th, momentum has begun to flow this week. A more extensive study, SEQURUS-2, has already started to provide a “statistically robust evaluation” of caffeine on the PK of SQ-administered ipilimumab. Topline study results will be presented at the 14th Annual Bioprocessing Summit in mid-August. So the clock has begun ticking, and CMRA stock continues hitting new July highs.

Athersys, Inc. (NASDAQ: ATHX)

best penny stocks to buy biotech stocks Athersys ATHX stockchart

The exciting thing about penny stocks is that you can have one that slides for months, hits new 52-week lows, then seemingly out of nowhere, explodes. That is the case with Athersys in the stock market today. Shares of ATHX stock recently tested fresh lows on Tuesday but have bounced back nearly 100%.

[Read More] What to Know About Buying Penny Stocks on July 28th

What’s going on with Athersys? This week the company announced its next round of financial results. August 11th, after the close, is the time to mark down if ATHX stock is on your radar. The company is developing its MultiStem cell therapy product for neurological, inflammatory, immune, and cardiovascular indications. Several trials are currently ongoing evaluating its regenerative potential.

In the most recent Key Opinion Leader panel events, Athersys discussed its TREASURE study studying MultiStem for ischemic stroke. With the upcoming event in August, eyes could be on ATHX stock in hopes of new data or guidance on its pipeline.


best penny stocks to buy biotech stocks InflaRx IFRX stockchart

Is InflaRX on your penny stocks list today? If so, you probably saw headlines earlier in the week regarding an Emergency Use Authorization application announced for its vilobelimab. The company reported plans for the EUA application for using its candidate to treat critically ill COVID-19 patients. The move came after encouraging FDA interactions were held in a Type B meeting.

“Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients,” said Prof. Niels C. Riedemann, CEO and Founder of InflaRx in this week’s update.

Vilobelimab also received FDA Fast Track designation in treating ulcerative pyoderma gangrenosum. The skin disorder is being studied after the application of the drug candidate. With multiple use cases, new designations, and current studies in process and planned, there could be several things to follow with IFRX stock.

Revelation Biosciences Inc. (NASDAQ: REVB)

best penny stocks to buy biotech stocks Revelation Biosciences REVB stockchart

Shares of REVB stock popped late in the week this week, thanks to a turnaround in sentiment. Revelation specializes in immunologic-based therapies and recently announced a $5 million offering to push the ball down the field with the development of its REVTx-99b, REVTx-200, and REVTx-300 treatment platforms.

[Read More] Penny Stocks To Buy Now? 4 To Watch During July Fed Announcement

Since the offering is expected to close today, REVB stock is back in focus with new cash in hand. Its lead candidate, REVTx-99b, recently completed the dosing of its Phase 1b CLEAR clinical study. In a mid-June update, James Rolke, Chief Executive Officer of Revelation, explained, “We are excited to complete enrollment in this study and look forward to reporting the results in the third quarter of 2022.”

In true fashion, the company reported this data on July 22nd after the closing bell. The primary endpoint to evaluate the effects of REVTx-99b versus placebo on safety and tolerability was met. Now the plan is to assess the treatment candidate further.

Chimerix (NASDAQ: CMRX)

best penny stocks to buy biotech stocks Chimerix CMRX stockchart

Monkeypox stocks are still heating up the newsfeeds in the stock market today. Following earlier reports that the WHO declared the monkeypox spread a Global Health Emergency, this basket of biotech stocks has flourished in recent weeks. Led by the likes of Siga Technologies (NASDAQ: SIGA), plenty of cheaper stocks with a monkeypox treatment platform are gaining steam.

Emergent BioSolutions Inc. (NYSE: EBS), another monkeypox stock to watch, bought exclusive worldwide rights to Chimerix’s Tembexa. In a May update, Paul Williams, SVP government/MCM business at Emergent, said, “This transaction expands and further diversifies our medical countermeasures business with the addition of a small molecule therapeutic that aligns with the government’s smallpox preparedness strategy.”

With exposure to the latest monkeypox trend, CMRX is one of the penny stocks to watch. Keep in mind that since many of these companies are moving on speculation and broad headlines, sentiment and price movement, for that matter, can quickly change.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…



Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading